


**CLAIMS**

We claim:

1. A compound of Formula I



5



wherein:

Q is CH or N;

- 10  $R^1$  is tetrazolyl,  $\text{MeCONHSO}_2^-$ ,  $\text{PhCONHSO}_2^-$ ,  $\text{R}^5\text{O}_2\text{C}(\text{CH}_2)_{0-3}\text{CONHSO}_2^-$ ,





- $R^2$  is  $\text{R}^6$ ,  $-\text{CH}_2\text{Ar}^1$ ,  $-\text{CHPh}_2$ ,  $-\text{CH}_2\text{CO}(4\text{-FPh})$ ,  $-\text{CH}_2\text{CO}(4\text{-CF}_3\text{Ph})$ , or  $-\text{CH}_2\text{CONp}$  where Np is naphthyl;

- 15  $R^3$  is  $\text{C}_{5-7}\text{cycloalkyl}$ ;

$R^4$  is hydrogen,  $\text{Ar}^2$ , or  $\text{Ar}^3$ ;

$\text{Ar}^1$  is selected from the following group: phenyl, halophenyl,






- Ar<sup>2</sup> is phenyl, naphthyl, or biphenyl, optionally substituted with 1-3 substituents  
 5 selected from the group comprising halogen, C<sub>1-6</sub> alkyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>sulfoxy, C<sub>1-2</sub>perfluoroalkyl, hydroxy, formyl, C<sub>1-6</sub>alkylcarbonyl, cyano, nitro, C<sub>1-6</sub>alkylamido, CO<sub>2</sub>R<sup>5</sup>, CONR<sup>5</sup>R<sup>5</sup>, C<sub>1-6</sub>alkylsulfonamido, and dioxolane;

- Ar<sup>3</sup> is thienyl, furanyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl,  
 10 quinolinyl, or pyrimidinyl optionally substituted with 1-2 substituents selected from the group comprising C<sub>1-6</sub>alkyl, formyl, acetoxy, trifluoroacetoxy, and t-butoxycarbonyl;

R<sup>5</sup> is hydrogen or C<sub>1-6</sub>alkyl;

R<sup>6</sup> is halogen, methoxy, CO<sub>2</sub>R<sup>5</sup> or CONR<sup>7</sup>R<sup>8</sup>;


- 15 R<sup>7</sup> and R<sup>8</sup> are independently hydrogen, C<sub>1-6</sub>alkyl, -CH(Me)CO<sub>2</sub>R<sup>5</sup>,



- or R<sup>7</sup> and R<sup>8</sup> taken together with the nitrogen to which they are attached  
 form pyrrolidine, morpholine, piperidine, 4-hydroxypiperidine,  
 20 piperazine, or 4-methylpiperazine;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. A compound of claim 1 wherein  $R^3$  is cyclohexyl.



3. A compound of claim 1 wherein  $R^1$  is tetrazolyl and  $R^2$  is

5

4. A compound of claim 3 wherein  $R^4$  is  $Ar^2$ .

5. A compound of claim 4 wherein  $R^3$  is cyclohexyl.

6. A compound of claim 3 wherein  $R^4$  is  $Ar^3$ .

- 10 7. A compound of claim 6 wherein  $R^3$  is cyclohexyl.

8. A compound of claim 3 wherein  $R^4$  is hydrogen.

9. A compound of claim 8 wherein  $R^3$  is cyclohexyl.

15

10. A compound of claim 1 wherein  $R^2$  is  $-CH_2Ar^1$ .

11. A compound of claim 10 wherein  $R^3$  is cyclohexyl.

- 20 12. A composition useful for treating hepatitis C comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

13. A method for treating hepatitis C comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.

25